MedTrace Logo

Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection

NCT05586815 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2023-01-18

No results posted yet for this study

Summary

Acinetobacter baumannii causes severe infections (pneumonia, bacteremia, organ space) with high lethality in hospitalised critically ill patients. It can acquire resistance to all classes of antibiotics (multidrug resistance, MDR) except an 'old' drug, colistin, which may be the only therapeutic option. The addition of minocycline to colistin has been shown to be synergistic in vitro, and may be promising in vivo, but this combination has not been limited to case report or case series in comparison with colistin alone.

Conditions

  • Acinetobacter Infections

Interventions

DRUG

Colistin

150 mg every 8 hours intravenously for at least 7 and up to a maximum of 28 days

DRUG

Minocycline

200 mg every 12 hours orally for at least 7 and up to a maximum of 28 days

DRUG

Placebo

Capsule without active compound

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • Adhiratha Boonyasiri, MD · Mahidol University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-10
Primary Completion
2024-01-31
Completion
2024-06-30

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05586815 on ClinicalTrials.gov